By Ellen Bardash | April 5, 2024
U.S. District Judge Angel Kelley wrote that Latham & Watkins-repped Homology Medicines Inc. "had no duty to disclose data in real time."
By Amanda Bronstad | April 3, 2024
Plaintiffs lawyers in the Ozempic multidistrict litigation organized a leadership team of 30 attorneys, but one Florida attorney objected to the proposed slate, which she says appears to be composed of 'repeat players.'
By Charles Toutant | March 29, 2024
A 2020 verdict allowed Teva and other companies to produce generic versions of Vascepa. But Teva allegedly had to scale back its launch because of an inability to obtain the key ingredient, the suit said.
By Amanda Bronstad | March 15, 2024
Express Scripts Inc., a pharmacy benefit manager facing upcoming bellwether trials over the opioid crisis, filed a March 13 brief referencing a subpoena that Motley Rice member Linda Singer sent to the company on behalf of the city of Chicago.
The Legal Intelligencer | News
By Aleeza Furman | March 15, 2024
"What I want is to avoid asking for continuances and asking for delay and asking for new dates. Just pick your poison and stick with it," Pratter told the approximately 70 people gathered in her courtroom Thursday.
By Amanda Bronstad | February 27, 2024
U.S. District Judge Dan Polster, who is weighing a disqualification motion in the opioid multidistrict litigation, raised concerns this month about Motley Rice obtaining confidential information while representing the state of Hawaii, the District of Columbia and the city of Chicago in other cases.
By Brian Lee | February 5, 2024
Chief Judge Elizabeth Wolford of U.S. District Court, Western District in Rochester wrote that the plaintiffs failed to present a viable claim under the Sherman Act.
The Legal Intelligencer | News
By Amanda Bronstad | February 2, 2024
On Friday, the U.S. Judicial Panel on Multidistrict Litigation ordered 55 cases filed against Eli Lilly and Novo Nordisk over Ozempic, Mounjaro and other medications be coordinated into multidistrict litigation.
By Charles Toutant | January 29, 2024
On Sept. 12, 2023, the FDA issued a report on phenylephrine, saying that there were no safety issues found with its use as a decongestant but there were also no benefits, the suit said.
By Charles Toutant | January 19, 2024
Courts have consistently rejected challenges under the Takings Clause to federal health care programs that seek to limit costs, according to an amicus curiae brief by a panel of nine nationally recognized experts in Medicare and medical finance.
Presented by BigVoodoo
The National Law Journal honors attorneys & judges who've made a remarkable difference in the legal profession in the D.C. area.
The New England Legal Awards serves as a testament to the outstanding contributions and achievements made by legal professionals.
Join the industry's top owners, investors, developers, brokers & financiers at THE MULTIFAMILY EVENT OF THE YEAR!
Mid sized NYC Personal Injury Defense Firm seeking to immediately hire several attorneys to join our firm. Preferred candidates are those w...
Mid-size Parsippany based law firm with a statewide practice is searching for a full-time motivated associate litigation attorney with 3-5 y...
Description: Fox Rothschild has an opening in Princeton, NJ for an associate in the Litigation Department. The ideal candidate will have tw...